Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7086307 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL3467519 | 1.00 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL20942840 | 0.86 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18245295 | 0.86 | SLC6A2 (0.73) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2877540 | 0.84 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2877536 | 0.84 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3468271 | 0.84 | CHRM2 (0.53) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL7812301 | 0.83 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14920380 | 0.80 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8245301 | 0.79 | TACR1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2568805-B1 | A MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | XVIVO PERFUSION AB (SE) | 2019-05-01 | — | — | EP | claimed |
| US-20160354359-A1 | COMPOSITION COMPRISING NOR-ADRENALINE AND A NET INHIBITOR FOR ADMINISTERING TO A BRAIN-DEAD, HEART-BEATING POTENTIAL ORGAN DONOR | XVIVO PERFUSION AB (SE) | 2016-12-08 | — | — | US | claimed |
| US-20030144289-A1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | claimed |
| US-6440996-B1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | GEORGETOWN UNIVERSITY | 2002-08-27 | — | — | US | claimed |
| EP-2568805-B1 | A MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | XVIVO PERFUSION AB (SE) | 2019-05-01 | — | — | EP | disclosed |
| US-10271540-B2 | Medical fluid, a method of treatment and use of the fluid | XVIVO PERFUSION AB (SE) | 2019-04-30 | — | — | US | disclosed |
| US-20160354359-A1 | COMPOSITION COMPRISING NOR-ADRENALINE AND A NET INHIBITOR FOR ADMINISTERING TO A BRAIN-DEAD, HEART-BEATING POTENTIAL ORGAN DONOR | XVIVO PERFUSION AB (SE) | 2016-12-08 | — | — | US | disclosed |
| US-20160338343-A1 | MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | XVIVO PERFUSION AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-20130065218-A1 | MEDICAL FLUID, A METHOD OF TREATMENT AND USE OF THE FLUID | VIVOLINE MEDICAL AB (SE) | 2013-03-14 | — | — | US | disclosed |
| US-6605621-B1 | Safe and effective detoxification after treating drug addiction, or diseases wherein cocaine is administered | GEORGETOWN UNIVERSITY | 2003-08-12 | — | — | US | disclosed |
| US-20030144289-A1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | disclosed |
| US-6440996-B1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | GEORGETOWN UNIVERSITY | 2002-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144289-A1 | Monomeric and dimeric heterocycles, and therapeutic uses thereof | HAX1, MLX, XDH | SLC6A2 258/4885SLC6A4 631/4885SLC6A3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.